Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.165
-0.035 (-1.60%)
Mar 14, 2025, 10:56 AM EDT - Market open
Gain Therapeutics Employees
As of December 31, 2023, Gain Therapeutics had 32 total employees, including 29 full-time and 3 part-time employees. The number of employees increased by 1 or 3.23% compared to the previous year.
Employees
32
Change (1Y)
1
Growth (1Y)
3.23%
Revenue / Employee
n/a
Profits / Employee
-$667,717
Market Cap
57.42M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 32 | 1 | 3.23% |
Dec 31, 2022 | 31 | 2 | 6.90% |
Dec 31, 2021 | 29 | 15 | 107.14% |
Dec 31, 2020 | 14 | 10 | 250.00% |
Dec 31, 2019 | 4 | - | - |
GANX News
- 3 hours ago - Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - GlobeNewsWire
- 8 days ago - Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
- 2 months ago - Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease - GlobeNewsWire
- 3 months ago - Gain Therapeutics To Present At Biotech Showcase 2025 - GlobeNewsWire
- 5 months ago - Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - GlobeNewsWire